StemCell Therapy

The House of Representatives passed a bill for allotment of funds in an emergency pool earlier this week, which is to be used to counter the damaging effects of the coronavirus outbreak is expected to have on the domestic economy.

Let us analyze which stocks are expected to benefit from this emergency stash.

House Allocates $8 Billion to Emergency Funds

On Mar 4, the House passeda legislation that allocates more than $8 billion to emergency funds to battle against the spread of coronavirus. The bill won by a voting ratio of 415-2. Republican lawmakers Ken Buck of Colorado and Andy Biggs of Arizona were the only members who voted unfavorably.

The emergency funds aim to provide more than $3 billion for vaccine research and $2.2 billion for efforts in prevention and preparedness. Medical tests and vaccine research to combat the pandemic are urgent tasks right now, which many biotechnology firms in the country are working on actively.

Companies, such as Moderna, Inc. MRNA, Inovio Pharmaceuticals, Inc. INO and Vir Biotechnology, Inc. VIR are currently in the process of developing the much-needed vaccines.

The congressional spending proposal is considerably higher than the $2.5 billion that the White House had proposed in late February. The bill also authorizes about $500 million to allow Medicare providers to offer telehealth services, which would benefit elderly patients to receive care in the comforts of their homes.

The bill is now headed to the Senate for approval. Should it be passed effectively, it will then make its way to President Donald Trumps desk, who is expected to give a green signal. Trump had earlier indicated at a news conference that he would spend whatever is appropriate to fight the COVID-19 outbreak.

After all, death toll in the United States climbed to 11 and minimum 138 are infected. Of the 11, 10 deaths were confirmed from Washington while one was registered in California. Globally, the pandemic claimed more than 3,100 lives.

Story continues

3 Stocks in Focus

We have, therefore, handpicked three vital stocks that are actively developing vaccines to address the novel coronavirus. One may take a closer look at these.

Modernais a clinical stage biotechnology company. Last week, the company saidthat its first batch of vaccine against the COVID-19 disease, called mRNA-1273, was ready for the government to test on humans.

The Zacks Consensus Estimate for Modernas current-year earnings has moved 5% north in the past 60 days. Shares of this company, which belongs to the Zacks Medical - Biomedical and Geneticsindustry, have risen 40.5% against the industrys decline of 2.6% on a year-to-date basis. (Read more)

Moderna carries a Zacks Rank #2 (Buy). You can seethe complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

Inovio Pharmaceuticalson Mar 4 announcedan accelerated timeline to develop its DNA vaccine INO-4800 to battle COVID-19. Inovio's President & CEO Dr. J. Joseph Kim mentioned this accelerated timeline at the U.S. Coronavirus Task Force meeting at the White House on Mar 2.

Inovio Pharmaceuticals carries a Zacks Rank #3. Shares of this company, which belongs to the Zacks Medical - Biomedical and Geneticsindustry, have risen 143.2% against the industrys decline of 2.6% on a year-to-date basis.

Vir Biotechnologyis a clinical-stage immunology company. The firm, along with Alnylam Pharmaceuticals, Inc. ALNY, announcedon Mar 4 that the two companies would expand their continuing collaboration to make an attempt to develop RNA interference treatments for SARS-CoV-2.

Vir Biotechnology carries a Zacks Rank #3. Shares of this company, which belongs to the Zacks Medical - Biomedical and Geneticsindustry, have risen 257% against the industrys decline of 2.7% on a year-to-date basis.

Free: Zacks Single Best Stock Set to Double

Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the companys drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

See 5 Stocks Set to Double>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportModerna, Inc. (MRNA) : Free Stock Analysis ReportAlnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis ReportInovio Pharmaceuticals, Inc. (INO) : Free Stock Analysis ReportVir Biotechnology, Inc. (VIR) : Free Stock Analysis ReportTo read this article on Zacks.com click here.

Read this article:
House Okays $8 Billion Funds to Combat COVID-19: 3 Winners - Yahoo Finance

This entry was posted on March 6, 2020 at 5:44 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |